Recent innovations in technology have gifted us with novel ways to collect, track, and analyze patient data. These digital tools can provide quantifiable indicators or biomarkers of a patient's physiological, behavioral and/or cognitive state. In this talk, I will begin by giving an overview of the AI's potential applications in healthcare, will then introduce an AI-assisted technology as a digital biomarker for assessing cognitive performance and monitoring it in health and disease. Accurate and repeatable measures of cognition have the potential to be used as a marker of disease activity in Alzheimer's, multiple sclerosis (MS) and other brain disorders. For frequent cognitive assessments, digital biomarkers have an advantage over fluid biomarkers, given their lower cost, accessibility, the possibility of remote administration and easier integration into routine clinical practice.
Dr. Khaligh-Razavi is a neuroscientist and entrepreneur; co-founder of Cognetivity ltd, UK; and assistant professor at Royan Institute, Brain and Cognitive Sciences Dept. With a background in computer science and machine learning, he completed his PhD in 2014 at the MRC Cognition and Brain Sciences Unit, Cambridge University, studying visual object recognition in human and machine. After that he became a postdoctoral researcher at the Computer Science and Artificial Intelligence Laboratory (CSAIL) at the Massachusetts Institute of Technology (MIT), studying the human brain using multimodal neuroimaging techniques and computational modelling. During this time, he was also affiliated with Harvard Catalyst (The Harvard University Clinical and Translational Science Centre), where he has worked on medical device development.